You just read:

Phase 3 Study Results Supporting U.S. FDA and European Commission Approvals of STELARA® in the Treatment of Moderately to Severely Active Crohn's Disease Published in The New England Journal of Medicine

News provided by

Janssen Pharmaceutical Companies

16 Nov, 2016, 17:00 ET